Erstellt von fchar99
Alnylam Pharmace. diskutieren
Alnylam Pharmace.
WKN: A0CBCK / Symbol: ALNY / Name: Alnylam Pharms / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
351,60 €
1,59 %
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $300.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $300.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at HC Wainwright from $400.00 to $500.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $300.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $310.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Royal Bank of Canada from $310.00 to $330.00. They now have an "outperform" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Citigroup Inc. from $338.00 to $351.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating. They now have a $328.00 price target on the stock, up previously from $280.00.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Stifel Nicolaus from $300.00 to $345.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is now covered by analysts at Redburn Atlantic. They set a "buy" rating and a $353.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $500.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $320.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Chardan Capital from $300.00 to $325.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at JPMorgan Chase & Co. from $330.00 to $338.00. They now have an "overweight" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in Northrop Grumman Corp. diskutieren